

Maduck Sean  
 Form 3  
 February 09, 2018

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |   |   |  |   |  |
|--|---|---|--|---|--|
| <p>1. Name and Address of Reporting Person *</p> <p>^ Maduck Sean</p> <p>(Last) (First) (Middle)</p> <p>C/O CORCEPT<br/>             THERAPEUTICS<br/>             INCORPORATED, ^ 149<br/>             COMMONWEALTH DRIVE</p> <p>(Street)</p> <p>MENLO PARK, ^ CA ^ 94025</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>02/07/2018</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>CORCEPT THERAPEUTICS INC [CORT]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br/> <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other<br/>             (give title below) (specify below)<br/>             See Remarks</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person<br/> <input type="checkbox"/> Form filed by More than One Reporting Person</p> |
|--|---|---|--|---|--|

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock                       | 10,024   | D   | ^  |
| Common Stock                       | 10,000   | I   | See Footnote <sup>(1)</sup>                              |
| Common Stock                       | 10,000   | I   | See Footnote <sup>(2)</sup>                              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

## Edgar Filing: Maduck Sean - Form 3

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 3. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 4) |                                  | 4. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 5. Ownership<br>Form of<br>Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5) |
|---|--|--------------------|--|----------------------------------|--|--|---|
|   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount or<br>Number of<br>Shares |  |  |   |
| Stock Option (Right to Buy)                   | Â <u>(3)</u>   | 11/01/2022         | Common Stock   | 45,000                           | \$ 2.24  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(3)</u>   | 01/30/2023         | Common Stock   | 20,000                           | \$ 2.08  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(3)</u>   | 11/19/2023         | Common Stock   | 25,000                           | \$ 1.92  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(3)</u>   | 02/06/2024         | Common Stock   | 40,000                           | \$ 3.02  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(4)</u>   | 08/07/2024         | Common Stock   | 100,000                          | \$ 2.61  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(5)</u>   | 02/18/2025         | Common Stock   | 250,000                          | \$ 3.29  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(6)</u>   | 02/26/2026         | Common Stock   | 150,000                          | \$ 3.88  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(7)</u>   | 05/02/2026         | Common Stock   | 150,000                          | \$ 5.05  | D  | Â   |
| Stock Option (Right to Buy)                   | Â <u>(8)</u>   | 02/10/2027         | Common Stock   | 400,000                          | \$ 8.27  | D  | Â   |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |               |       |
|--|---------------|-----------|---------------|-------|
|  | Director      | 10% Owner | Officer       | Other |
| Maduck Sean<br>C/O CORCEPT THERAPEUTICS INCORPORATED<br>149 COMMONWEALTH DRIVE<br>MENLO PARK, CA 94025 | Â             | Â         | Â See Remarks | Â     |

## Signatures

/s/ Sean Maduck                      02/09/2018

\_\_Signature of                      Date  
Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: Maduck Sean - Form 3

Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

(2) Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.

(3) Fully exercisable.

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of August 1, 2014, so that the total number of shares subject to this option becomes fully vested and exercisable on August 1, 2018.

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 18, 2015, so that the total number of shares subject to this option becomes fully vested and exercisable on February 18, 2019.

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 26, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on February 26, 2020.

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of April 27, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on April 27, 2020.

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021.

^

### Remarks:

Senior Vice President, Commercial

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.